Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

NCT00934544 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolitinib
DRUG: Best Available Therapy (BAT)

Sponsor

Novartis Pharmaceuticals